非酒精性脂肪性肝炎患者肝移植后第一年死亡风险高于其他病因肝病患者
该研究基于美国器官共享联合网络登记数据,比较了因非酒精性脂肪性肝炎(NASH)、丙型肝炎病毒(HCV)相关肝病和酒精相关性肝病(ALD)接受肝移植患者的结局。在2016-2017年移植的患者中,NASH患者移植后1年生存比例显著低于HCV和ALD患者,且1年内调整死亡风险显著高于ALD患者;NASH患者心血管或脑血管疾病死亡占比最高。
要点
- 2016-2017年移植者中,NASH患者1年生存比例显著低于HCV(P=0.004)和ALD(P<0.001)患者。
- NASH患者1年内调整死亡风险显著高于ALD患者(HR 1.37;P=0.03),与有无肝细胞癌无关。
- NASH患者心血管或脑血管疾病死亡占11.5%,高于HCV的7.0%和ALD的9.6%(P<0.001)。
核心结论
- 在2016-2017年接受肝移植的患者中,NASH患者移植后1年内死亡风险高于HCV相关肝病或ALD患者。
- 死亡风险随年龄增加而升高,且NASH患者死于心血管或脑血管疾病的风险更高。
研究设计与样本
- 分析美国器官共享联合网络登记数据,纳入因NASH接受肝移植者6344例、因慢性HCV感染肝硬化接受肝移植者17037例、因ALD接受肝移植者9279例。
- 移植时间段为2008-2010年、2011-2013年、2014-2015年、2016-2017年。
- 采用Cox回归模型比较不同组结局,并校正供者和受者特征。
主要发现
- 2016-2017年移植者中,NASH患者移植后1年生存比例显著低于HCV患者(P=0.004)和ALD患者(P<0.001)。
- 该时间段内,NASH患者1年内调整死亡风险显著高于ALD患者(HR 1.37;P=0.03),无论有无肝细胞癌。
- 与50岁以下患者相比,NASH患者总死亡风险的HR在50-59岁为1.31(P=0.02)、60-64岁为1.66(P<0.001)、65-69岁为2.08(P<0.001)、≥70岁为2.66(P<0.001)。
- NASH患者心血管或脑血管疾病死亡占比最高,为11.5%;HCV感染患者为7.0%,ALD患者为9.6%(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: An increasing number of patients with non-alcoholic steatohepatitis (NASH) require liver transplantation. We compared outcomes of patients with liver diseases of different etiologies (NASH, hepatitis C virus [HCV]-associated liver disease, and alcohol-associated liver disease [ALD]). METHODS: We analyzed data from the United Network for Organ Sharing registry on 6344 patients who underwent liver transplantation for NASH, 17,037 for cirrhosis from chronic HCV infection, and 9279 for ALD. We collected data from patients who underwent liver transplantation during the following time periods: 2008-2010, 2011-2013, 2014-2015, 2016-2017. We compared outcomes of different groups using Cox regression models, adjusting for donor and recipient characteristics. RESULTS: For patients who underwent liver transplantation during 2016-2017, a significantly lower proportion of patients with NASH survived for 1 year after transplantation than patients with HCV (P = .004) or ALD (P < .001). During this time period, the adjusted risk of death within 1 year was significantly higher for patients with NASH than with ALD (hazard ratio, 1.37; P = .03), regardless of the presence of hepatocellular carcinoma. The effects of increasing age were greatest among patients with NASH: compared to patients younger than 50 years, hazard ratios for overall mortality were 1.31 for patients 50-59 years (P = .02), 1.66 for patients 60-64 years (P < .001), 2.08 for patients 65-69 years (P < .001), and 2.66 and for patients and ≥70 years (P < .001). Mortality from cardiovascular or cerebrovascular disease(s) was highest among patients with NASH, accounting for 11.5% of deaths, compared to 7.0% of deaths in patients with HCV infection and 9.6% in patients with ALD (P < .001). CONCLUSIONS: In an analysis of data from patients who underwent liver transplantation during 2016-2017, we found the risk of death within 1 year after transplant was higher among patients with NASH than HCV-associated liver disease or ALD. Risk of death increased with age, and patients with NASH have a higher risk of death from cardiovascular or cerebrovascular disease.
引用
- Nagai S, Collins K, Chau LC, et al. Increased Risk of Death in First Year After Liver Transplantation Among Patients With Nonalcoholic Steatohepatitis vs Liver Disease of Other Etiologies. Clin Gastroenterol Hepatol. 2019. PMID: 31004758. doi:10.1016/j.cgh.2019.04.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。